PharmaCyte’s novel approach could emerge as one of the most effective and diverse cancer treatment platforms in the market for solid tumors of all kinds and could be worth billions of dollars.

The market may be flirting with year highs but this incredibly undervalued stock has not yet made its move, which we think could occur before year-end. Here’s why, as outlined in a new sponsored research update:

Recent and pending events infer that the road to approval and marketing of Pharmacyte's flagship pancreatic cancer treatment has been dramatically shortened, potentially leading to a banner year 2016 for PharmaCyte shareholders.

This low valuation medical device company is set to transform its segment of the $3 billion electrophysiology (EP) marketplace. EP studies are used in conjunction with cardiac ablation procedures for patients suffering from atrial fibrillation (AF) and other conditions. The Company’s flagship platform fulfills an unmet need by enhancing the efficacy and diagnostic value of EP studies. Moreover, it reduces the frequency of and the time it takes to complete EP studies used in cardiac ablation procedures.

PMCB's approach to diabetes therapy could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes, and could potentially replace them.

Last week was an incredible week for PharmaCyte Biotech (OTC – PMCB), which prompted us to issue a new research update. Major industry and company news released last week should take investor sentiment and the stock to a new level regarding the potential and timing of FDA approval for PharmaCyte’s pancreatic cancer treatment for patients with locally advanced pancreatic cancer. 

PharmaCyte Biotech’s Cell Encapsulation Approach to Treat Diabetes Could Prove Superior to Other Encapsulation Techniques 

Following decades of failed research, a great deal of attention and funding have recently turned toward utilizing encapsulation techniques to treat Type 1 diabetes (T1D), including the approach championed by PharmaCyte Biotech (OTCQB – PMCB - $0.1152 – Spec Buy), which in turn, is likely to drive clinical and investor interest in the Company.

Investors that overlook PharmaCyte Biotech’s (OTCQB – PMCB - $0.1035 – Spec Buy) breakthrough technology to treat diabetes may be kicking themselves in the end, given the low valuation afforded this innovative biotech pioneer.  Success in PharmaCyte Biotech’s diabetes treatment studies alone could be worth billions of dollars and change the lives of millions.

PharmaCyte Biotech (OTC – PMCB) may be undervalued today but that is not likely to last. See why it could quickly return to its highs of six months ago.

With so many stocks still in the valuation stratosphere we are pleased to announce that we are initiating coverage of Chanticleer Holdings, Inc. (NASDAQ – HOTR - $1.31), a low-priced, fast-growing, yet low valuation company. 

In fact, Chanticleer is one of the fastest-growing and most attractively priced companies in the entire fast casual dining space. The Company owns and operates over 50 restaurant brands in the U.S, South Africa, Australia, and Europe. Chanticleer is a franchisee owner of 15 Hooters and dozens of restaurants in the wildly popular “better burger” segment.  Total sales for both the second quarter of 2015 and the first half of the year exceeded 60%.